Anzeige
Mehr »
Mittwoch, 11.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
63 Leser
Artikel bewerten:
(0)

Global Pharmaceutical Hot Melt Extrusion Equipment Market Research Report 2017

DUBLIN, November 29, 2017 /PRNewswire/ --

The "Global Pharmaceutical Hot Melt Extrusion Equipment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2017 to 2025" report has been added to Research and Markets' offering.

Research and Markets Logo

The global pharmaceutical hot melt extrusion equipment market was valued at US$ 26.1 Mn in 2016, and is expected to reach US$ 39 Mn by 2025, expanding at a CAGR of 4.5% from 2017 to 2025.

The use of hot melt extrusion technology in pharmaceutical application is steadily increasing due to its ability of manufacture novel drugs with improved bioavailability. Development of novel drugs with challenged solubility and bioavailability has urged the adoption of HME process in drug-delivery systems, particularly in solid dosage forms and transdermal patches. Hot melt extrusion involves the application of heat, agitation and pressure through extrusion channel for mixing materials and forcing them into desired form. Growth in number of novel drugs with challenged bioavailability and the urgency for introducing such drugs in the market are the key drivers contributing to the growth in demand for hot melt extrusion in pharmaceutical application.

Among the considered extruder types, twin-screw extruders (TSE) are the most widely used process for development of solid dosage forms and it uses both distributive and dispersive mixing. Driven by the FDA's process analytical technology initiative (PAT), the use of TSE in pharmaceutical manufacturing has been adopted by every major pharmaceutical manufacturer. The process analytical technology initiative has encouraged formulation of new dosages with TSE technology. Further efforts are also being taken for designing TSE systems for testing early-stage materials that are available only in minimal quantities.

Geographically, North America is the largest regional market for pharmaceutical hot melt extrusion equipment with a market share of over 35% in 2016. Existence of a multitude of pharmaceutical manufacturers that have adopted HME systems in drug manufacturing and widespread installation of HME in cGMP practices will ensure the dominance of North America market on the global front. The demand for HME systems in Europe pharmaceutical industry is also expected to remain steady during the forecast period. High demand for novel drug manufacturing technologies mainly drive the Europe market. However, growing CMO and research activities will facilitate the faster growth of Asia Pacific market.

Presence of a several manufacturers has made the competition in the global pharmaceutical hot melt extrusion equipment fragmented, with a handful of companies enjoying global prominence.

Some of the major players in the global pharmaceutical hot melt extrusion equipment market are Baker Perkins Ltd., Coperion GmbH, Gabler GmbH & Co. KG, Milacron Holdings Corp., Leistritz Advanced Technologies Corp., Thermo Fisher Scientific, Inc. and Xtrutech Ltd.

Key Topics Covered:

Chapter 1. Preface

Chapter 2. Executive Summary

2.1. Global Pharmaceutical Hot Melt Extrusion Equipment Market Portraiture


2.1.1. Global Pharmaceutical Hot Melt Extrusion Equipment Market, by Product, 2016


2.1.2. Global Pharmaceutical Hot Melt Extrusion Equipment Market, by Usage Area, 2016


2.1.3. Global Pharmaceutical Hot Melt Extrusion Equipment Market, by Geography, 2016

Chapter 3. Pharmaceutical Hot Melt Extrusion Equipment: Market Dynamics and Outlook

3.1. Market Definition and Overview


3.2. Drivers


3.3. Challenges


3.4. Opportunities


3.5. Value Chain Analysis


3.6. Porter's Five Forces Model

Chapter 4. Global Pharmaceutical Hot Melt Extrusion Equipment Market, by Product, 2015 - 2025 (US$ Mn)

4.1. Overview


4.2. Attractive Investment Proposition, by Product


4.3. RAM Extruders


4.4. Radial Sceen Equipment


4.5. Roll and Screw Extruders


4.5.1. Single-screw extruders (SSEs)


4.5.2. Twin-screw extruders (TSEs)


4.5.3. Multi-screw extruders (MSEs)

Chapter 5. Global Pharmaceutical Hot Melt Extrusion Equipment Market, by Usage Area, 2015 - 2025 (US$ Mn)

5.1. Overview


5.2. Attractive Investment Proposition, by Usage Area


5.3. Research and Academia


5.4. Contract Manufacturing Organization


5.5. Pharmaceutical Companies

Chapter 6. Global Pharmaceutical Hot Melt Extrusion Equipment Market, by Application (Qualitative Information)

6.1. Overview


6.2. Attractive Investment Proposition, by Application


6.3. Bioavailability Enhancement


6.4. Microencapsulation


6.5. Targeted Drug Delivery


6.6. Taste Masking


6.7. Films


6.8. Others (Implants, Sustained-Release Preparations, Nanotechnology, Floating Drug Delivery System)

Chapter 7. Global Pharmaceutical Hot Melt Extrusion Equipment Market, by Geography, 2015 - 2025

Chapter 8. Company Profiles

  • Baker Perkins Ltd.
  • Coperion GmbH
  • Gabler GmbH & Co. KG
  • Milacron Holdings Corp.
  • Leistritz Advanced Technologies Corp.
  • Thermo Fisher Scientific, Inc.
  • Xtrutech Ltd.

For more information about this report visit https://www.researchandmarkets.com/research/dwngph/global


Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

© 2017 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.